Synchronous multifocal tumors are common in the hepatobiliary and pancreatic system but because of similarities in their histological features, oncologists have difficulty in identifying their precise tissue clonal origin through routine histopathological methods. To address this problem and assist in more precise diagnosis, we developed a computational approach for tissue origin diagnosis based on naive Bayes algorithm (TOD-Bayes) using ubiquitous RNA-Seq data. Massive tissue-specific RNA-Seq data sets were first obtained from The Cancer Genome Atlas (TCGA) and~1,000 feature genes were used to train and validate the TOD-Bayes algorithm. The accuracy of the model was >95% based on tenfold cross validation by the data from TCGA. A total of 18 clinical cancer samples (including six negative controls) with definitive tissue origin were subsequently used for external validation and 17 of the 18 samples were classified correctly in our study (94.4%). Furthermore, we included as cases studies seven tumor samples, taken from two individuals who suffered from synchronous multifocal tumors across tissues, where the efforts to make a definitive primary cancer diagnosis by traditional diagnostic methods had failed. Using our TOD-Bayes analysis, the two clinical test cases were successfully diagnosed as pancreatic cancer (PC) and cholangiocarcinoma (CC), respectively, in agreement with their clinical outcomes. Based on our findings, we believe that the TOD-Bayes algorithm is a powerful novel methodology to accurately identify the tissue origin of synchronous multifocal tumors of unknown primary cancers using RNA-Seq data and an important step toward more precision-based medicine in cancer diagnosis and treatment.
Introduction
Synchronous multifocal tumors across tissues are common in clinic, most of which are metastatic, and a small number of which are multiple primary tumors. [1] [2] [3] [4] Failure to make a definitive tissue origin diagnosis is a main cause of poor prognosis for these patients. As a result, doctors are often faced with the dilemma of deciding on what course of clinical management is best: immediate surgery or system treatment (e.g., chemotherapy and targeted therapy). [5] [6] [7] [8] In system treatment, tumors derived from different tissues require different chemotherapy regimens, and even targeted therapy of identical oncogenic mutations requires knowledge of tissue of origin. 9, 10 The accurate identification of the tissue clonal origin is the premise of precision medicine in cancer treatment.
The hepatobiliary and pancreatic system has similar cellular origins in the embryo. Cancers in this system have very similar anatomical and histological features, making identification of tissue clonal origin challenging. Traditional identification methods based on histopathology and immunohistochemistry (IHC) are often unsuccessful especially in case of synchronous multifocal tumors across tissues. For example, it is very difficult to identify intrahepatic cholangiocarcinoma (ICC) and metastatic pancreatic cancer (PC) by liver biopsy, because different primary tumors share the same biomarkers and possible expression changes in the biomarkers can occur when the tumor status shifts from primary to metastatic. 11, 12 In addition, a further complication is that about 5% of the primary cancers in the liver are combined hepatocellular-cholangiocarcinoma (cHCC-CC), composed of cells with histopathological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). [13] [14] [15] Therefore, finding new and accurate methods to identify tissue origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system is of critical need.
Researchers have been looking for other more reliable means to identify the origin of tissue of synchronous multifocal tumors. Initially, cytogenetic studies were carried out in the hopes that this approach would be beneficial. [16] [17] [18] [19] However, synchronous multifocal tumors are cytogenetically heterogeneous and cannot be distinguished by several chromosomal aberrations. Recently, researchers also tried to analyze tissue origin of metastatic deposits in the setting of synchronous multiple malignancies by massively parallel sequencing platform. 4, 20 Through efforts of The Cancer Genome Atlas (TCGA) Project (https://tcga-data.nci.nih. gov), six different omics datasets (i.e., DNA copy number variation, DNA methylation, mRNA expression, microRNA expression, protein expression, and somatic point mutation) of 34 different cancer types have become available. Our previous study showed that patterns of copy number variation (CNV) varied across tissue types, and subtyping of the tumors from different types based on the genomic CNVs from TCGA revealed a correlation with tissue. 21 However, recent research from Hoadley et al. confirmed that subtyping of tumors based on mRNA expression data (RNA-seq) had the most significant correlation with tissue origin. 22 Up to now, several bioinformatics methods (e.g., decision trees, 23, 24 support vector machines, [25] [26] [27] [28] and others 29 ) have been used to analyze tissue origin of tumors using RNA-seq data. These studies are all based on microarray-based gene expression signatures to identify a "molecular fingerprint" including tens to hundreds of genes to discriminate cancers of different tissue origin. For some types of carcinomas, the accuracy of these methods were <90%. Many of these studies avoided incorporating cancers of the hepatobiliary and pancreatic system 24, 27 because of the difficulties associated with determining the tissue origin in this system. Given this limitation, we postulated that genome-wide assessment of gene expression would be a more suitable method for accurately determining tissue clonal origin of cancer, especially given the large amount of data currently available in public databases. However, such an approach was limited by lacking of appropriate bioinformatics tools. Therefore, we developed a naive Bayes model based algorithm, dubbed TOD-Bayes, using the top 1,000 feature genes in the hepatobiliary and pancreatic system present in the RNASeq data from TCGA. By using an innovative bioinformatics tool, we aimed to develop a genome-wide algorithm to accurately identify tissue origin of synchronous multifocal tumors across tissues.
Materials and Methods

Sample collection and RNA-Seq data curation
A total of 18 formalin-fixed paraffin-embedded (FFPE) cancer tissue specimens found with definitive tissue origins in the hepatobiliary and pancreatic system (three PCs, four CCs, five HCCs, and six mCRCs, metastatic colorectal cancers in liver) were collected for RNA-Seq analysis and use in external validation of our generated computational method. The proportion of cancer cells in each tumor specimens was independently reviewed and evaluated by three histopathologists to confirm the tumor cell content when possible. Only samples with >50% tumor cells were included in the analysis. Total RNAs were isolated from these samples and pair-end sequenced by Illumina HiSeq 4000. Tissue samples from two patients who suffered from synchronous multifocal tumors across tissues where definitive primary cancer diagnosis by traditional histopathology or IHC methods in the hepatobiliary and pancreatic system What's new? Multiple tumors that develop from a single primary tumor within a short timeframe are often anatomically and histologically similar. As a result, such tumors frequently obscure the identification of tissue clonal origin, complicating diagnosis. To improve the accuracy of tissue origin identification, the authors of this report developed a Bayes algorithm using gene data sets specific for hepatobiliary and pancreatic tumors. The algorithm correctly classified tissue clonal origin more than 95% of the time for clinical samples of pancreatic cancer, cholangiocarcinoma, and hepatocellular carcinoma. The algorithm was also expanded to the precise diagnosis of cancer of unknown primary.
were not successful in diagnosis were selected for analysis as case studies of the application of the algorithm. Nucleic acid extraction and sequencing was performed as described above.
Written informed consent was obtained from the patient for genomic examination and analyses of the samples. The Internal Review Board of The First Affiliated Hospital, School of Medicine, Zhejiang University approved the genetic analysis of the patients.
Clinical history of two case study cancer samples Case study 1 is a patient with a 6 month history of recurrent abdominal pain and jaundice and a higher than normal level of carbohydrate antigen 199 (CA-199) (486 U/mL; upper limit of 37 U/mL). Computerized tomography revealed three separate cellular masses in his pancreatic tail, upper common bile duct, and omentum, respectively. Case study 2 was a patient found to have two synchronous nodules in the left liver and pancreas during a routine health examination. The patient reported no visible symptoms and had no abnormal tumor markers. Both patients agreed to surgery and following the procedures three tumors were removed in the first patient (one pancreatic tumor, one common bile duct tumor, and one omentum tumor), and four tumors were found in the second patient (one liver tumor, one pancreatic tumor, and two mesenteric lymph nodes tumors). Histopathological and immunohistochemical analysis of these two cases revealed moderately differentiated adenocarcinomas with positive cytokeratin 7 (CK7) or 19 (CK19). Whether the two cases are multiple primary cancers or metastatic cancers, and the respective tissue origin of these masses are all equivocal, whether by clinical manifestation, radiology, or traditional histopathology and IHC methods.
Statistical and bioinformatic analyses of RNA-Seq data FASTQC 30 was used for initial QC metrics (base quality distribution) and NGS QC toolkit 31 was used to trim low-quality ends. RNA-Seq reads were mapped to the reference genome (hg19) using MapSplice. 32 Gene expression was quantified for the transcript algorithms corresponding to TCGA GAF 2.13, using RSEM4 and normalized within-sample to a fixed upper quartile. R software (3.1.3) 33 (R package 'hclust') was used for conducting the hierarchical clustering tree of the samples by the gene expression levels in the UPGMA (unweighted pair group method with arithmetic mean) method. The publicly available RNA-Seq cancer data sets were downloaded from TCGA including three cancer types (PC: 179; CC: 36; HCC: 374) (details in Supporting Information).
Tissue-dependent clustering: Consensus Cluster Plus R-package 34 was used to identify clusters in the data using 1,000 iterations, 80% sample re-sampling from 2 to 20 clusters using hierarchical clustering with average inner Linkage and final Linkage and Pearson correlation as the similarity metric (details in Supporting Information).
The TOD-Bayes algorithm for inferring origin of synchronous multifocal tumors
The naive Bayes algorithm employs a simplified version of the Bayes formula to decide to which class a novel instance belongs. 35 In our study, we used the naive Bayes algorithm to decide synchronous multifocal tumors belong to which cancer types. The posterior probability of each class is calculated, given the feature values present in the instance; the instance is assigned the class with the highest probability. The equation below shows the naive Bayes formula.
The left side of the equation is the posterior probability of class C i given the feature values, <v 1 ; v 2 ; . . . ; v n >, observed in the instance to be classified. The denominator of the right side of the equation is often omitted because it is a constant which is easily computed if one requires that the posterior probabilities of the classes sum to one. In addition, we used an effective filtering approach termed correlation-based feature selection (CFS), 36 to identify the genes highly correlated with the class but not correlated with each other for the naive Bayes. As shown in the equation below, CFS evaluates a subset of features by considering the individual predictive ability of each feature along with the degree of redundancy between them.
CFS s is the score of a feature subset S containing k features, r cf is the average feature to class correlation, and r ff is the average feature to feature correlation.
Three steps were included in the TOD-Bayes algorithm based analysis for identifying the clonal origin of the tumor samples in the hepatobiliary and pancreatic system (Fig. 1a ).
Step 1: To discriminate whether the samples could be excluded from the hepatobiliary and pancreatic system, we calculated the item-consensus value of each sample based on the analysis of consensus cluster. If the item-consensus value was >90%, we accepted that the sample belonged to the hepatobiliary and pancreatic system, 37 otherwise, the sample was included in the "Others" category of cancer types.
Step 2: We then identified the liver origin cancer and the pancreas and biliary duct origin of the cancer. To accomplish this we selected the most informative genes for class detection, generated a dataset including the variable genes, and measured by median absolute deviation (MAD). We then used the Consensus Clustering method 34 for unsupervised class discovery of the cancer samples from TCGA. After that, we used an effective filter approach, CFS 36 ( Fig. 1) , to get the feature genes highly correlated with the class, yet uncorrelated with each other. Transcript reads were normalized with log transformation followed by quantile normalization to account for variations (e.g., differences in the amount of starting material and reported transcript units) between and within datasets. The samples were then divided into ten randomly generated subsets, each with an equal proportion of samples of the cancer type of interest. A tenfold cross-validation method based on naive Bayes model was used to train the algorithm on ninefold and test it on the remaining onefold. The accuracy of the gene expression signature-generating computational algorithm was calculated based on this algorithm (Fig. 1b) . After that, we tested our clinical cancer samples in the TOD-Bayes.
Step 3: To further investigate the origins of the pancreas and biliary duct cancer types, we consensus clustered the pancreas and biliary duct cancer samples. Then we applied the method mentioned in
Step 2 to further identify the tissue origin of the cancer samples. In addition, the tenfold cross-validation method based on naive Bayes was used to calculate the accuracy of TOD-Bayes. A detailed pipeline of TOD-Bayes, including some R packages used by our study, is available at our lab website (http://ibi.zju. edu.cn/bioinplant/tools/).
Results
The RNA-Seq data generated and used by our study
In order to develop an accurate method to predict the clonal origin of tumor samples, publicly available RNA-Seq data from 589 known/identified samples of HCC, PC, and CC were obtained from TCGA for our study. The number of samples was sufficient for classical analysis of tenfold cross-validation (see details in the next section). To further validate our method, a total of 18 samples, including 12 cancer samples of HCC (5), PC (3) and CC (4) and six mCRCs in liver as negative control were collected and sequenced by our study (Table 1 ). An average of 20 Gb of RNA-Seq raw data were generated for each sample (Supporting Information Table 1 and Fig. 1 ).
As case studies, synchronous multifocal hepatobiliary and pancreatic tumors (three in patient 1 and four in patient 2, respectively) were collected from two patients for which the clonal origin of the tumors could not be determined by traditional diagnostic approaches and the transcriptomes sequenced to an average of 20 Gb RNA-Seq data (Supporting Information Table 1 and Fig. 1 ). Their RNA-Seq data were then used to predict the tissue clonal origin of each multifocal tumor using the algorithm developed by our study.
The development and accuracy of TOD-Bayes for inferring the origin of synchronous multifocal tumors
Using RNA-Seq data from TCGA as training data, a computational algorithm for tissue origin diagnosis of cancer based on naive Bayes method(TOD-Bayes), was developed to identify the origin of the tumor samples by tissue-specific gene expression levels of HCC, pancreatic carcinoma, and cholangiocarcinoma (details see Methods). For the purpose of selecting the most informative genes for classification detection, we generated a dataset including the top 10,000 most variable expressed genes (actual count: 9,987) measured by MAD (Fig. 1) as expressed tag genes. We then used the Consensus Clustering method for unsupervised class discovery of the cancer samples from TCGA. The Consensus Clustering method involves subsampling from a set of items and determines clustering of specified cluster counts (k). This resulted in the identification of two main classes among the three cancer types (Figs. 2ad) . We used different cluster counts (from 2 to 6) to consensus cluster the data from TCGA. The data can be correctly clustered based on the cancer types when k 5 2 in the liver, biliary duct and pancreas samples (Fig. 2a in upper panel) . Based on the cumulative distribution functions (CDF) of the consensus matrices and the relative change in area under the CDF curve for k 52 and other counts, a similar curve or no significant area change for k 5 2 comparing to 3 or more higher counts were observed. We found 97.3% of the samples in the first class were HCC types and 92.6% of the samples in the second class were PC and CC types. Furthermore, we also generated the cluster-consensus for the two clusters which showed that both of the two clusters had over 98.7% of the cluster-consensus. These results suggested the HCC tumor type have a distinct gene expression patterns from the PC and CC types. Thus, we were able to discriminate HCC tumors from PC and CC tumors at the second step (Fig. 1) . In addition, we generated the item consensus for each sample. We selected the samples with >95% of the item-consensus in each cluster for the further analysis.
After CFS, we got 1,000 feature genes (actual count: 943) (Supporting Information Table 2 ) from the expressed tag gene sets for TOD-Bayes. The accuracy of the TOD-Bayes for the two cancer types was calculated based on tenfold cross-validation method in naive Bayes algorithm (Supporting Information  Table 3a ). The percentage of the correctly classified instances was 96.6% (569 among the total 589 TCGA samples). The results showed that the precision of TOD-Bayes was >98.1% in the classification of HCC, and >95.7% in the classification of CC and PC (Supporting Information Table 4 ).
To further investigate the origins of PC and CC types, we consensus clustered the PC and CC cancer samples from TCGA at the second step (Fig. 1) . This identified subclasses among the two cancer types (Figs. 2ad lower panel) . We subsequently applied different cluster counts (from 2 to 8) to consensus cluster the data from TCGA and found that the data correctly predicts the cancer types when k 5 6 in the CC and PC samples (Fig. 2a lower   panel) . Again, based on the cumulative distribution functions (CDF) of the consensus matrices and the relative change in area under the CDF curve for k 5 6 and other counts, a similar curve or no significant area change for k 5 6 comparing to 7 or more higher counts were observed. We found that 93.8% of the CC samples could be classified into one subcategory. The PC samples were divided in several subcategories. So we classified the cancer types in two categories (CC type or PC type) based on the cancer type. The accuracy of the TOD-Bayes method for the CC and PC types was calculated based on tenfold cross-validation method in naive Bayes algorithm. The percentage of the correctly classified instances was >94.8% (204 among the total 215 CC and PC samples) (Supporting Information Table 3b ).
External validation of the TOD-Bayes
We used RNA-Seq data generated specifically for our study in external validation testing in order to determine whether our algorithm could accurately identify tissue clonal origins in the general Chinese population. We sequenced the transcriptomes from 12 cancer samples including five HCC samples, four CC samples, and three PC samples and calculated the gene expression levels (Table 1) . At the same time, we also sequenced the transcriptomes from six mCRCs in the liver as negative controls for the validation. Based on the feature genes, a heatmap including the 18 clinical samples with 589 TCGA samples was constructed by hierarchical clustering (Fig. 3) . A complex phylogeny was observed among tissues in the hepatobiliary and pancreatic system as previous studies and failed to provide a clear tissue origin diagnosis. We tested TOD-Bayes using all the samples including the negative control. Then, we used the method to identify the cancer samples to calculate the accuracy rate of our method in naive Bayes algorithm.
To determine whether the samples could be excluded from the hepatobiliary and pancreatic system, we calculated 
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the item-consensus of each sample based on the two clusters in the analysis of consensus cluster. We found that all 12 cancer samples had >0.95 of the item-consensus value from the classified clusters. In contrast, the item-consensus results of the six mCRC samples had <0.60 from any of the classified clusters, which are all significantly lower than the cut-off item-consensus value (0.90).Therefore, the liver metastasis from colon cancer samples (Supporting Information Fig. 1) were not included in the further analysis. These results suggested that the TOD-Bayes method was able to exclude the cancer types which did not belong to the liver cancer types, biliary duct cancer type and pancreas cancer types.
As described in the TOD-Bayes protocol, we first identified the HCC and the PC/CC origin cancer at the first step. Among the total 12 cancer samples, the percentage of the correctly classified instances was >91.7% (11/12 samples) (Supporting Information Table 5 ; for a detailed accuracy by class see Supporting Information Table 6 ). The one outlier was an intrahepatic CC (ICC) sample that was misjudged as HCC (see Discussion for details). Among the 18 clinical samples (including six negative controls) used for external validation, 17 samples were classified correctly. Taken together the overall accuracy of TOD-Bayes was 94.4% in the external validation for the 18 samples (Supporting Information Table 5 ). Overall, these findings provide strong support that our method can accurately identify the origin of tumors in the hepatobiliary and pancreatic system using RNA-Seq data.
Two case studies of synchronous multifocal tumors
We further applied our algorithm in two clinical cases involving patients who suffered from synchronous multifocal tumors of the hepatobiliary and pancreatic system. We first discriminated whether the cancer samples belonged to the hepatobiliary and pancreatic system using all of the seven tested samples from two patients (Step 1). The results showed that the origin of all the cancer samples in the two case studies were from hepatobiliary and pancreatic system (i.e., the 0.90 item-consensus cut-off value). Therefore, we used the TOD-Bayes to predict their origin.
In Case study 1, the patient suffered from synchronous multifocal tumors in three tissues. As shown in Fig. 2 , we found the data can be correctly classified based on the cancer types when k 5 2 and 6 in HCC, CC, and PC samples. So we used k 5 2 and 3 to consensus cluster the samples at first step, and k 5 6 and 7 to consensus cluster the samples in case studies at second step. All three of the patient's tumors were classified as a type of PC by consensus clustering analysis and the cut-off value of item-consensus (Figs. 4a and 4b) , indicating that the patient likely had pancreatic cancer that metastasized to the biliary duct and omentum. We subsequently applied TOD-Bayes to identify the origin of three tumor tissues in this case, and all of the tumor tissues were discriminated as PC consistent with the consensus clustering analysis. Taken together, our data suggested that the tissue clonal origin of the three metastatic tumors in Case study 1 was the pancreas.
In Case study 2, the patient was found to have synchronous multifocal tumors in four sites. Based on the prediction results of consensus clustering analysis all four of the patient's samples were CC type with the values of itemconsensus of 0.937 (Figs. 4a and 4b ). This suggested that the patient initially had ICC which subsequently metastasized to the pancreas and mesenteric lymph nodes. When we applied TOD-Bayes to identify the tissue clonal origin of the four tumor samples in Case 2, our result also indicated that the four samples were all classified as CC type. Accordingly, we suggested that the tissue clonal origin of the four metastatic tumors in Case study 2 were in the intrahepatic biliary duct (Supporting Information Fig. 1) .
TOD-Bayes also provides a brief report for each sample that includes data quality and identification of tumor tissue origin for the target sample (an example of report see Supporting Information Table 7) . A summary of TOD-Bayes reports for the three tumor tissues in Case 1 is illustrated in Fig. 5 (a summary for all 25 tumor tissue samples by our study are provided as Supporting Information Fig. 1 ). According to the reports, at least 57 million RNA-Seq reads have been generated and mapped into the reference genome for each tumor tissue samples of Case study 1, which covered all of the 1,000 feature genes used by TOD-Bayes. The three samples of Case study 1 were all identified as CC or PC in the 
Discussion
In our study, we described the development of an effective and efficient computational tool based on Bayesian classification (TOD-Bayes) to accurately identify the tissue clonal origin of synchronous multifocal tumors in hepatobiliary and pancreatic system. The overall accuracy was >95.0% for internal verification based on TCGA data. External validation based on analyzing RNA-Seq data from 18 Chinese cancer samples with four different types, achieved an overall accuracy of >94.4% (17 among 18 samples). We also applied the TOD-Bayes algorithm to judge the tissue origins of two patients who suffered from synchronous multifocal tumors in the hepatobiliary and pancreatic system but failed to make a definitive primary cancer diagnosis by traditional methods. The results showed both were metastatic cancers. The first patient died after half one year with multiple liver metastasis. If his initial diagnosis is pancreatic cancer with multiple metastases, surgery may be avoided and a more suitable systemic treatment could be initiated. The second patient accepted our tissue origin analysis one month after surgery, and was diagnosed as ICC with lymph node metastasis (invading pancreas). After chemotherapy treatment with gemcitabine and platinum, the patient continues to survive to the present. The two patients' clinical outcomes are consistent with our tissue origin diagnosis, implying the possibility of application of the TOD-Bayes algorithm in clinic.
In the case of synchronous multifocal tumors of the hepatobiliary and pancreatic system, the pathological and IHC methods tend to lose its effectiveness. In general, regardless of cell morphology or the presence of IHC markers, it remains difficult to accurately distinguish primary ICC and metastatic PC in liver.
38 CK7, CK19, and CK20 proteins are often detected in both PC and CC 12, 39 and human pancreatic cancer fusion #2 (HPC2) proteins are observed in 80% of PCs, and 32% of CCs. Similarly, N-cadherin was observed in 27% of PCs, and 58% of CCs, separately. 40 For these reasons we chose to first divide CC and PC into group (as described elsewhere in the text). Furthermore, prior studies aimed at tissue origin diagnosis of cancers using gene expression signatures in the hepatobiliary and pancreatic system are extremely limited and many have significant experimental shortcomings, such as insufficient sample size from a single tumor(only 13, 10, and 17sample size for HCC, CC and PC, separately 27 ), failure to include CC 28, 41 and low sensitivity for PC(38.9%). 28 To our knowledge, this is the first RNASeq based computational algorithm to specifically identify tissue origin of cancers in the hepatobiliary and pancreatic system.
TOD-Bayes algorithm is based on RNA-Seq analysis but not microarray probes or markers based. We used a widegenomic gene set including 10,000 most variable expressed genes in the consensus clustering step in TOD-Bayes. Based on the results of CFS, we selected 1,000 feature genes from the 10,000 gene set, instead of tens to hundreds of the individual marker genes for the tissue origin diagnosis of cancers. Gene expression is regulated by a complex cascade of events. Genetic and epigenetic events in cognate binding partners, 42 competitive endogenous RNAs 43 and upstream regulators 44 can all contribute to aberrant expression of oncogenes, which suggesting that the diagnose of tumor tissue origin based on limited marker genes' expression were not all-inclusive and even not so accurate. In other words, compared to previous individual gene expression signatures depended methods, our algorithm used genome-wide information including more gene expression regulation factors, through which we can identify the tissue origin of cancers more accurately. In addition, we used two steps rather than one to predict the tissue origin of tumors, basing on both unsupervised and supervised algorithms. Just as we have shown, a complex phylogeny was observed among tissues in the hepatobiliary and pancreatic system and failed to provide a clear tissue origin diagnosis based on traditional hierarchical clustering (Fig. 3) . We used consensus cluster method (unsupervised algorithm) to reclassify the known origin cancer samples at first. After that, we used a naive Bayes algorithm-based method (supervised algorithm) to identify the tissue origin of synchronous multifocal tumors in the hepatobiliary and pancreatic system. The naive Bayes algorithm is very well suited for examining gene expression profiles, because computation of the posterior distribution is all that is required for making the desired inferences, such as the computation of quantiles, standard deviations, credible sets, and predictions. 45 Because of the data structure of gene expression profiles, frequentist inference using parametric algorithms does not appear feasible, and computing variances and other quantities based on asymptotic theory does not appear tenable. Thus, the naive Bayes algorithm appears to be better suited for dealing with these types of problems. Furthermore, most previous studies only included publicly available data for internal as well as external validation tests, leading to an overfitting and reducing the reliability of the algorithm.
We have performed a comparison of our protocol with the current algorithm-based methods such as that reported in the study by Wei et al., 41 which had a good performance for the tissue origin diagnosis. To do this, and be as accurate in our comparison as possible, we used the same data set and the same methodology (i.e., stepwise logistic regression-based method) described by Wei et al. By comparison, the accuracy of our TOD-Bayes method was slightly higher than that Wei et al. found using the model based on the biomarker signatures in the liver (95.7% vs. 93.6%) and pancreas (95.0% vs. 92.0%); in the bile duct there was no significant difference between the methods (94.4% vs. 95.0%) (details in Supporting Information). In light of our findings that the TOD-Bayes method provides improvement in tissue origin diagnosis, and the potential exists that both independent methods can be used simultaneously to cross check patient diagnosis and thereby improving clinical outcomes.
In our study, we sequenced 18 cancer samples from Chinese population (four different cancer types included) rather than simply using the public data to validate the accuracy of our computational method. Because most of the cancer samples we used as the training dataset in TCGA were from Western populations. The accuracy of our method was >94.4% in identifying tissue origin of tumors with histologically confirmed origin in the hepatobiliary and pancreatic system. So our results suggested that we could accurately identify the tissue origin of the cancer samples from Chinese population on our algorithm. However, one of the 18 clinical samples with histologically confirmed origin failed to be identified correctly in our study. It was an ICC sample which was misjudged as HCC. In this research, the content of the tumor cells in our cancer samples were >50%. We suggested the heterogeneity in the bulk sample might have caused the incorrect classification of this sample. It also suggested that better sample preparation, such as microdissection, might improve the precision of our method. However, we could not rule out the possibility that this patient might have a cHCC-CC cancer. Additionally, another three of the four ICC samples were all accurately classified as CC type, suggesting that our algorithm had high cancer specificity and could conquer the problem of the influence of carcinoma adjacent tissues.
This new algorithm has a good expansibility because it can be trained on data from different types of cancer, making it useful in the identification of different kinds of tissue origins in addition to those of the hepatobiliary and pancreatic system. Additionally, if we included training data across more tissues, the method could be used for determining the origins of cancers of unknown primary (CUP) tissues. Based on the consensus cluster method we first calculated the value of the item-consensus for each sample to discriminate whether the sample belonged to target tumor types or "Others." Then we identified the accurate tissue origin (target tumor types included in the method) using the naive Bayes based algorithm. CUP accounts for approximately 5% of all newly diagnosed cancers. 46 As precision medicine plays a larger role in the clinical management of cancer, precise diagnosis for CUP is more urgent. The existence of type "Others" transforms the method from a "closed system" to an "open system," and in this way we can reduce the false positive rate and increase the applicability of the algorithm.
Obviously, the FFPE samples (used by our study) are always a challenge for RNA analysis because of their tendency to exhibit high degradation levels. However, they are undoubtedly the most accessible samples in clinics. Fortunately, the TOD-Bayes algorithm is both less platformspecific and less sample type limited, thereby allowing easier integration of data from multiple laboratories. Therefore, we anticipate it having broad clinical application in synchronous multifocal tumors diagnosis in particular involving unknown primary cancers.
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